successful treatment of refractory behçet's disease with the tnf-α blocker infliximab

Successful Treatment of Refractory Behçet's Disease with the TNF-α Blocker Infliximab

Successful treatment of refractory hughes stovin syndrome with infliximab

Introduction Hughes-Stovin Syndrome (HSS) is a very rare clinical disorder characterized by pulmonary artery aneurysms and peripheral venous thrombosis. Typical symptoms are recurrent fever, chills, haemoptysis and it usually affects young men. The natural course of the illness is usually fatal because of fulminant haemoptysis. The aetiology of Hughes-Stovin syndrome is still unknown; however i...

The Successful Treatment of Refractory Polyarteritis Nodosa Using Infliximab

Polyarteritis nodosa (PAN), characterized by arteritis of medium-sized blood vessels, is usually treated with a combination of glucocorticoids and immunosuppressants; however, some cases are refractory to these treatments. We herein report the case of a man with PAN that was refractory to various immunosuppressive treatments, including cyclophosphamide, methotrexate, and rituximab. After inflix...

Successful treatment of genital ulcers with infliximab in Behcet's disease.

R ecurrent oral and genital aphthous ulcerations are the hallmarks of Behçet’s disease. Up to now the various clinical manifestations in Behçet’s disease have been treated with limited success. Recently, clinical observations have reported dramatic responses on clinical signs and symptoms in patients treated with tumour necrosis factor a (TNFa) blocking drugs, including severe mucocutaneous, ga...

Infliximab treatment for refractory Kawasaki disease with coronary artery aneurysm.

Tumor necrosis factor-alpha (TNF-alpha) is considered to be 1 of the factors that induce vasculitis, including coronary artery aneurysm (CA), in Kawasaki disease (KD), because the blood concentration of TNF-alpha is higher in patients with CA compared with those without. Therefore, an anti-TNF-alphaagent (infliximab) was administered to a 1-month-old girl with refractory KD complicated by CA an...

Infliximab therapy for the treatment of refractory ocular inflammatory disease.

OBJECTIVE To report the outcomes of infliximab therapy in the treatment of ocular inflammatory disease refractory to traditional immunomodulatory therapy (IMT). METHODS We retrospectively reviewed the medical records of 27 patients. All patients had noninfectious ocular inflammatory disease refractory to traditional IMT and received 5 mg/kg of infliximab at 2-week to 8-week intervals. Main ou...